Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 3/20 | 0.45 |
| ▸ | BUB1 | O43683 | 3/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | GUCY1A1 | Q02108 | 11/20 | 0.37 |
| ▸ | GUCY1B1 | Q02153 | 11/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12299623 | 0.89 | PDE5A (0.50) | PDE5ABUB1ADORA3KCNH2GUCY1A1 | |
| SCHEMBL12298808 | 0.87 | PDE5A (0.52) | PDE5ABUB1ADORA3KCNH2GUCY1A1 | |
| SCHEMBL28503512 | 0.84 | ADORA3 (0.47) | PDE5AADORA3KCNH2GUCY1A1GUCY1B1 | |
| SCHEMBL29379281 | 0.84 | ADORA3 (0.47) | PDE5AADORA3KCNH2GUCY1A1GUCY1B1 | |
| SCHEMBL255841 | 0.82 | ADORA3 (0.63) | PDE5AADORA3KCNH2GUCY1A1GUCY1B1 | |
| SCHEMBL12299208 | 0.79 | PDE5A (0.55) | PDE5ABUB1ADORA3KCNH2GUCY1A1 | |
| SCHEMBL10064748 | 0.78 | ADORA3 (0.62) | PDE5AADORA3KCNH2GUCY1A1GUCY1B1 | |
| SCHEMBL12299204 | 0.77 | KCNH2 (0.68) | PDE5ABUB1ADORA3KCNH2GUCY1A1 | |
| SCHEMBL12298814 | 0.77 | PDE5A (0.57) | PDE5ABUB1ADORA3KCNH2GUCY1A1 | |
| SCHEMBL12298800 | 0.76 | KCNH2 (0.55) | PDE5ABUB1ADORA3KCNH2GUCY1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130178475-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178475-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| WO-2011115804-A1 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178475-A1 | sGC STIMULATORS | GUCY1A1, PTGIS, GUCY1B1 | PDE5A 18/4885BUB1 4730/4885ADORA3 2877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.